
Available online at www.sciencedirect.com

ELSEVIER                                                                                     NEUROCHEMISTRY
                                                                                             International
                                                                                             www.elsevier.com/locate/neuint

**Review**

**Molecular and cellular function of ALS2/alsin: Implication of membrane dynamics in neuronal development and degeneration**

Shinji Hadano${}^{a,b}$, Ryota Kunita${}^{a}$, Asako Otomo${}^{b}$, Kyoko Suzuki-Utsunomiya${}^{b}$, Joh-E Ikeda${}^{a,b,c,*}$

${}^{a}$ Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan  
${}^{b}$ Department of Molecular Neuroscience, The Institute of Medical Sciences, Tokai University, Isehara, Kanagawa 259-1193, Japan  
${}^{c}$ Department of Paediatrics, Faculty of Medicine, University of Ottawa, Ontario K1H 8M5, Canada  

Received 28 March 2007; received in revised form 18 April 2007; accepted 19 April 2007  
Available online 4 May 2007

---

### Abstract

ALS2 is a causative gene for a juvenile autosomal recessive form of motor neuron diseases (MNDs), including amyotrophic lateral sclerosis 2 (ALS2), juvenile primary lateral sclerosis, and infantile-onset ascending hereditary spastic paralysis. These disorders are characterized by ascending degeneration of the upper motor neurons with or without lower motor neuron involvement. Thus far, a total of 12 independent ALS2 mutations, which include a small deletion, non-sense mutation, or missense mutation spreading widely across the entire coding sequence, are reported. They are predicted to result in either premature termination of translation or substitution of an evolutionarily conserved amino acid. Thus, a loss of functions in the ALS2-coded protein accounts for motor dysfunction and/or degeneration in the ALS2-linked MNDs. The ALS2 gene encodes a novel 184 kDa protein of 1657 amino acids, ALS2 or alsin, comprising three predicted guanine nucleotide exchange factor (GEF) domains: the N-terminal RCC1-like domain, the central Dbl homology and pleckstrin homology (DH/PH) domains, and the C-terminal vacuolar protein sorting 9 (VPS9) domain. In addition, eight consecutive membrane occupation and recognition nexus (MORN) motifs are noted in the region between DH/PH and VPS9 domains. ALS2 activates Rab5 small GTPase and involves in endosome/membrane trafficking and fusions in the cells, and also promotes neurite outgrowth in neuronal cultures. Further, a neuroprotective role for ALS2 against cytotoxicity; i.e., the mutant Cu/Zn-superoxide dismutase 1 (SOD1)-mediated toxicity, oxidative stress, and excitotoxicity, has recently been implied. This review outlines current understandings of the molecular and cellular functions of ALS2 and its related proteins on safeguarding the integrity of motor neurons, and sheds light on the molecular pathogenesis of MNDs as well as other conditions of neurodegenerative diseases.

© 2007 Elsevier Ltd. All rights reserved.

### Keywords: Motor neuron disease; Amyotrophic lateral sclerosis; ALS2/alsin; Guanine nucleotide exchange factor (GEF); Small GTPase; Endosome dynamics

---

### Contents

1. Introduction ..... 75
2. The ALS2 gene ..... 75
   2.1. Mutation ..... 75
   2.2. Structure and expression ..... 75
3. The ALS2 protein (ALS2/alsin) ..... 76
4. Function of ALS2 ..... 77
   4.1. Biochemical characteristics ..... 77
   4.2. Cellular biological characteristics ..... 78
   4.3. ALS2 knockout mice ..... 79
   4.4. ALS2-interacting and its related proteins ..... 80
      4.4.1. SOD1:Cu/Zn-superoxide dismutase ..... 80
      4.4.2. GRIP1: glutamate receptor interacting protein 1 ..... 81
      4.4.3. ALS2CL: ALS2 C-terminal like ..... 81

---

* Corresponding author at: Department of Molecular Life Sciences, Tokai University School of Medicine, 143 Shimokasuya, Isehara-city, Kanagawa 259-1193, Japan. Tel.: +81 463 91 5095; fax: +81 463 91 4993.  
E-mail address: jeikeda3@is.icc.u-tokai.ac.jp (J.-E. Ikeda).

0197-0186/$ – see front matter © 2007 Elsevier Ltd. All rights reserved.  
doi:10.1016/j.neuint.2007.04.010

S. Hadano et al./Neurochemistry International 51 (2007) 74–84

5. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1  
Mutations in the ALS2 gene in ALS2-linked motor neuron diseases  

| Mutations (Transcript or gene) $^{a}$ | Location | Type $^{b}$ | Mutant proteins $^{a}$ | Origin | Disease $^{c}$ | Phenotype $^{d}$ | References |
|--------------------------------------|----------|--------------|------------------------|--------|-----------------|---------------|------------|
| c.138delA                            | Exon 3   | fs           | A47fsX4                | Tunisian | ALS2            | U/L          | Hadano et al. (2001a) and Yang et al. (2001) |
| c.470G>A                             | Exon 4   | ms           | C157Y                  | Turkish | IAHSP           | U             | Eymard-Pierre et al. (2006) |
| c.553delA                            | Exon 4   | fs           | T185fsX5               | Turkish | ALS2            | U/L          | Kress et al. (2005) |
| c.1007_1008delTA                     | Exon 4   | fs           | I336fsX5               | Italian | IAHSP           | U             | Eymard-Pierre et al. (2002) |
| c.1425_1426delAG                     | Exon 5   | fs           | G476fsX71              | Kuwaiti | PLSJ            | U             | Hadano et al. (2001a) |
| IVS5(c.1472)-1G>                     | Intron 5 | fs           | V491fsX3               | French  | IAHSP           | U             | Eymard-Pierre et al. (2002) |
| T(C.1472_1481delTTTCCCCCAG)          |          |              |                        |         |                 |               |            |
| c.1619G>A                            | Exon 6   | ms           | G540E                  | Italian | PLSJ            | U             | Panzeri et al. (2006) |
| c.1867_1868delCT                     | Exon 9   | fs           | L623fsX24              | Saudi Arabian | PLSJ           | U             | Yang et al. (2001) |
| c.2537_2538delAT                     | Exon 13  | fs           | N846fsX13              | Italian | IAHSP           | U             | Eymard-Pierre et al. (2002) |
| c.2992C>T                            | Exon 18  | ns           | R998X                  | Israeli | IAHSP           | U             | Devon et al. (2003) |
| c.3619delA                           | Exon 23  | fs           | M1207X                 | Algerian | IAHSP           | U             | Eymard-Pierre et al. (2002) |
| c.4721delT                           | Exon 32  | fs           | V1574fsX44             | Pakistani | IAHSP           | U             | Gros-Louis et al. (2003) |

$^{a}$ The description of the mutations are accorded by den Dunnen and Antonarakis (Hum Mut 15, 7–12, 2000).  
$^{b}$ fs: frame shift, ms: missense, ns: nonsense.  
$^{c}$ ALS2: amyotrophic lateral sclerosis 2 (OMIM 205100), PLSJ: juvenile primary lateral sclerosis (OMIM 606353), IAHSP: infantile-onset ascending hereditary spastic paralysis (OMIM 607225).  
$^{d}$ U: upper motor neuron involvement, L: lower motor neuron involvement.

6.5 and 2.6 kb in various adult human tissues are detected by Northern blot analysis (Hadano et al., 2001a). Both transcripts are expressed ubiquitously with highest in the central nervous system (CNS), particularly in the cerebellum.

Murine ortholog for ALS2, officially designated as Als2, encompasses 6349 nt with a single ORF that is 4956 nt long (124–5079 nt), and is predicted to encode a 183 kDa protein consisting of 1651 aa. The entire ORF is well conserved between human and mouse (87% identity at DNA level). The Als2 short variant (Als2_S) of a 2955 nt with a single 2787-nt ORF encoding 928 aa (~100 kDa), which is produced by alternative splicing at the 5' donor site after exon 13, resulting in a premature stop codon after 74 amino acid residues in intron 13. Thus, the structure of the mouse Als2_S transcript is different from that of the human variant (Hadano et al., 2006).

In adult mouse CNS, the Als2 transcript is expressed to a variable degree in neuronal cells throughout the brain and spinal cord, particularly in neurons in the hippocampus, cerebellum, cerebral cortex, spinal gray matter (motor neurons), olfactory bulb, basal ganglia, and cranial nuclei (Hadano et al., 2001a) with most abundant in the granular layer of the cerebellum (Devon et al., 2005; Lein et al., 2007; Allen Brain Atlas, http://www.brain-map.org/welcome.do). During development, Als2 expression is limited at an early embryonic stage (E9.5–E12.5), but is gradually increased in CNS after E14.5 and reaches adult levels at P7 (Devon et al., 2005), reflecting that Als2 implicates in neuronal development.

### 3. The ALS2 protein (ALS2/alsin)

The human ALS2 and mouse Als2 genes encode proteins of 1657 aa and 1651 aa, respectively, which are called ALS2 (Hadano et al., 2001a) or alsin (Yang et al., 2001). Analysis of the predicted amino acid sequences identified a high level of sequence similarity throughout the entire region of human and

S. Hadano et al./Neurochemistry International 51 (2007) 74–84

Human ALS2

| RLD |
| --- |
| GCR |

| DH | PH | MORN motifs | VPS9 |
| --- | --- | --- | --- |
| 1 | 55 | 263 | 339 | 457 | 507 | 651 | 695 | 879 | 913 | 1007 | 1049 | 1243 | 1531 | 1654 | 1657aa |

Protein interacting module?

Rac1 binding region (Rac1GEF?)

Rab5 activating domain (Rab5GEF)

Oligomerization-mediating region

Fig. 1. Schematic representation of the human full-length ALS2 protein (ALS2) and its domains and motifs. ALS2 contains three predicted guanine nucleotide exchange factor (GEF) domains; i.e., RCC1-like domain (RLD), diffuse B cell lymphoma (Db1) homology (DH) and pleckstrin homology (PH) domains, and vacuolar protein sorting 9 (VPS9) domain. In addition, eight consecutive membrane occupation and recognition nexus (MORN) motifs are noted in the region between DH/PH and VPS9 domains. GCR stands for glucocorticoid receptor homologous region. A number of the functionally assigned regions are also noted.

to endosomal membrane compartments (Yamanaka et al., 2003; Topp et al., 2004; Devon et al., 2005). Notably, a significant amount of ALS2 is also present both in P2 (mitochondrial/synaptosomal) and S3 (soluble) fractions (Suzuki-Utsunomiya et al., unpublished). Further, it has been shown that ALS2 is enriched in a centrosome preparations purified from human cortical brain (Millecamps et al., 2005).

Immunohistochemical analysis of ALS2 using anti-ALS2 antibodies combined with neuronal and glial markers have revealed that ALS2 is expressed in various neurons, but not glial cells in mice (Hadano et al., 2006), consistent with the mRNA *in situ* hybridization studies. ALS2 is highly expressed in the granular layers of the cerebellum (Devon et al., 2005; Hadano et al., 2006), and shows the colocalization with some, but not all calbindin immunopositive Purkinje cells (Hadano et al., 2006). High magnification studies have demonstrated that ALS2 is mainly distributed in a diffused manner, but several dot or patchy stainings are consistently observed in soma as well as in dendrite, suggesting that ALS2 localizes not only in the cytosol but also onto vesicular and/or membranous compartments in neurons (Hadano et al., 2006). However, as there are still inconsistencies in the results of the immunohistochemical ALS2 localization (Devon et al., 2005; Hadano et al., 2006), further careful assessments will be required.

It is noted that there is currently no evidences for the expression of the expected truncated protein products in lymphoblasts from patients with confirmed homozygous mutation in ALS2 (Yamanaka et al., 2003) and short variants of the ALS2/Als2 genes (Otomo et al., 2003; Yamanaka et al., 2003; Hadano et al., 2006). Interestingly, both the mutated ALS2 and a naturally truncated isoform of ALS2 (ALS2_S) proteins are rapidly degraded in human cultured cells (Yamanaka et al., 2003; Eymard-Pierre et al., 2006), suggesting that loss of function coupled with protein instability may, in part, account for the pathogenesis underlying the ALS2-linked MNDs.

### 4. Function of ALS2

#### 4.1. Biochemical characteristics

The small GTPases act as binary switches by cycling between an inactive (GDP-bound) and an active (GTP-bound)
activity (Kunita et al., 2004). Moreover, the C-terminal region of ALS2 mediates the direct interaction between ALS2 and Rab5A (Otomo et al., 2003; Kunita et al., 2004; Hadano and Ikeda, 2005). Taken together, every element in the C-terminal ALS2 might be the determinant for the structural context of ALS2 that are indispensable for the ALS2-associated Rab5 GEF activity (Fig. 1).

Notably, there are additional genes encoding members of the Rab5 family, including Rab21, Rab22a, Rab31 (Rab22b), and Rab22c, other than Rab5A, Rab5B, and Rab5C, in the human genome (Stenmark and Olkkonen, 2001). Recently, Rabex-5, the well-studied VPS9 domain-containing Rab5GEF, has been shown to activate not only Rab5 but also Rab21 and Rab22a (Delprato et al., 2004). Further, another VPS9 domain-containing proteins, Varp and Gapex-5, exhibits a predominant catalytic activity on Rab21 and Rab31, respectively (Zhang et al., 2006; Lodhi et al., 2007). These findings suggest that each member of the VPS9-domain containing Rab5GEFs has a distinct catalytic property on the Rab5 GTPase family. The VPS9 domain-containing ALS2 protein also behaves as a GEF for Rab22a and Rab31 but not for Rab21 (Hadano et al., unpublished).

ALS2 contains the DH/PH domain in the middle, which is a hallmark of GEFs for Rho GTPase family. Indeed, it has been shown that ALS2 specifically binds to Rac1 in vitro in a DH/PH-domain dependent manner, but neither to Rac2, Rac3, Cdc42, RhoA, RhoB, RhoC, nor RhoG (Topp et al., 2004; Kanekura et al., 2005; Kunita et al., 2007). Further, overexpression of ALS2 in cultured cells marginally enhances the level of active Rac1, implying a potency of ALS2 to activate Rac1 (Topp et al., 2004; Kanekura et al., 2005; Tudor et al., 2005). However, as earlier mentioned, ALS2 does not possess the GEF activity on Rac1 in vitro (Otomo et al., 2003; Topp et al., 2004). Thus, the ALS2-associated Rac1GEF activity is still matter of conjecture (Fig. 1). Most recently, we have shown that ALS2 turns to be activated by Rac1, and thus ALS2 is a Rac1 effector rather than Rac1GEF (Kunita et al., 2007).

The N-terminal RLD of ALS2 conserves a seven-bladed propeller sequence that is a distinguishing feature of RCC1 as a Ran GEF (Hadano et al., 2001a; Topp et al., 2004). However, no significant ALS2-associated Ran GEF activity was detected in vitro (Otomo et al., 2003). Since RLDs are identified in many other proteins of diverse functions, the RLD in ALS2 might function as an interface between protein–protein or protein–lipid bindings rather than GEF (Fig. 1). Indeed, the ALS2-RLD modulates the association of ALS2 molecules to the membrane compartments (Yamanaka et al., 2003; Kunita et al., 2007). Further, the N-terminal region containing the RLD directly interacts with the C-terminal portion of ALS2, modulating the ALS2 distribution and activity in the cells (Kunita et al., 2007).

membrane edges of cellular peripheries (Otomo et al., 2003). Similar distribution profiles of endogenous ALS2 in NIH3T3 cells are observed (Topp et al., 2004). Vesicular ALS2 is partially colocalized with Rab5 and EEA1, markers for endosomes, indicating that ALS2 is the endosomal tribe (Otomo et al., 2003; Topp et al., 2004). Indeed, a loss of ALS2 results in the delayed fusion of epidermal growth factor (EGF)-positive endosomes in mouse embryonic fibroblasts (MEFs) (Hadano et al., 2006), supporting that endogenous ALS2 serves in Rab5-dependent endosome fusion (Fig. 2). Remarkably, ALS2 molecules on the leading membrane edges and ruffles significantly overlap with Rac1 (Topp et al., 2004). In a subset of cultured cells, some of ALS2 molecules are colocalized with the centrosomal markers, such as γ-tubulin and A kinase anchoring protein (AKAP-450) (Millecamps et al., 2005). It has also been reported that overexpression of ALS2 not only results in an abnormal endosomal phenotypes, but also in impairment of mitochondria trafficking and fragmentation of the Golgi apparatus (Millecamps et al., 2005). Thus, ALS2 is fairly committed in a wide range of membrane dynamics and cytoskeletal organizations in the cells.

A series of experiments using cultured cells expressing a truncated as well as missense ALS2 mutants has revealed that each ALS2 domain/region demonstrates specific subcellular tropism in vivo (Otomo et al., 2003; Yamanaka et al., 2003; Topp et al., 2004). The C-terminus of ALS2 carrying the MORN/VPS9 domains activates Rab5, and also mediates the endosomal localization for ALS2. On the other hand, the N-terminal RLD, in a context of full-length ALS2, acts suppressive in the membranous localization of ALS2 itself (Otomo et al., 2003), although the RLD-containing fragment itself associates with the membranous structures under certain conditions (Yamanaka et al., 2003; Kunita et al., 2007). Notably, the DH/PH domain constitutively promotes the MORN/VPS9 domain-mediated Rab5 activation and endosome fusions in vivo (Otomo et al., 2003). Further, the homo-oligomerization of ALS2 through its C-terminal regions is crucial for this ALS2-mediated endosome enlargement (Kunita et al., 2004). These findings suggest that the intracellular localization of ALS2 and its-associated Rab5GEF activity seem to be controlled by the internal domain(s) of ALS2, probably through the association with ALS2 itself and/or other protein or lipid molecules. Indeed, a pathogenic missense mutation in the RLD of ALS2 that results in the ALS2 mislocalization; i.e., loss of endosomal ALS2, has been reported (Panzeri et al., 2006). Thus, proper arrangement of the ALS2 subcellular localization may be crucial to exert the physiological ALS2 functions.

In neurons, endogenous and overexpressed ALS2 are found primarily on small vesicular/punctate structures both in cell bodies and elaborated somato-dendritic neurites of embryonic cortical, hippocampal, and motor neuronal cultures (Otomo et al., 2003; Topp et al., 2004; Jacquier et al., 2006). Some cytoplasmic ALS2 stainings are also observed (Otomo et al., 2003; Topp et al., 2004). At a matured stage of cultured neurons, vesicular ALS2 is present in either dendrites, axons, or the cell bodies, with no apparent polarized localization (Topp et al., 2004). Co-localization studies with Rab5 and EEA1

4.2. Cellular biological characteristics

In non-neuronal cultured cells, such as HeLa and COS-7 cells, ectopically expressed ALS2 diffusely distributes throughout cytoplasm with occasional localization to small vesicular structures in the perinuclear region and to the leading
S. Hadano et al./Neurochemistry International 51 (2007) 74–84

![Diagram](attachment:diagram.png)

Fig. 2. Schematic representation of a model for the intracellular function of ALS2. ALS2 mediates Rab5-dependent endosome fusion in the cells. A particular molecular signal(s) (e.g., Rac1) activates and recruits the ALS2 oligomer to early endosomal compartments through Rac1-activated macropinocytosis (Kunita et al., 2007), wherein ALS2 binds to Rab5 GTPase. ALS2 activates Rab5 via its associated Rab5GEF activity. Activated Rab5 (Rab5·GTP) further facilitates the formation of protein complex comprising downstream effector molecules such as early endosome auto-antigen 1 (EEA1) and soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins (not shown), and promotes endosome fusion. A loss of ALS2 may perturb endosomal trafficking and fusion, thereby leading to dysfunction of intracellular molecular signaling; e.g., insulin-like growth factor 1 (IGF1) or brain-derived neurotrophic factor (BDNF) (see text), and ultimately resulting in dysfunction/degeneration of neuronal cells.

demonstrate that ALS2 is present in endosomal compartments in neurons (Otomo et al., 2003). On the other hands, at an immature stage, ALS2 is enriched on the tip of axon with a dense localization to Rac1/actin-positive lamellipodia and vesicles at growth cones (Tudor et al., 2005; Jacquier et al., 2006). Compelling evidences for the functional aspects of ALS2 in neuronal endosome dynamics have been obtained from two independent studies. The Rab5-dependent fusion activity is significantly reduced in the brain cytosol from the Als2 knockout (KO) mice in comparison with wild-type (Devon et al., 2006). Further, siRNA-mediated knockdown of rat Als2 in cultured motor neurons results in smaller-sized EEA1-positive endosomes (Jacquier et al., 2006). Thus, endogenous ALS2 certainly plays an important role in Rab5-dependent endosome fusion in neurons. On the other hand, studies using the ALS2 overexpression as well as Als2 knockdown in conjunction with co-expression of the small GTPase have revealed that ALS2 stimulates neurite and axonal outgrowth in a Rac1-dependent manner (Tudor et al., 2005; Jacquier et al., 2006), suggesting that ALS2 enriched in growth cones may act as a modulator for neurite development. Collectively, ALS2 plays a role in membrane/vesicular trafficking and axonal outgrowth in neurons (Fig. 3), albeit the molecular linkages of these cellular events are still unclear.

### 4.3. ALS2 knockout mice

Als2 KO mice have been reported by five independent groups (Cai et al., 2005; Hadano et al., 2006; Devon et al., 2006; Yamanaka et al., 2006; Julien and Kriz, 2006). First two-lines of

Als2 KO mice were created by replacing the 39 bp of a BamHI fragment in exon 3 with the LacZ-NEO cassette (Cai et al., 2005) and the stop codon followed by the NEO cassette (Hadano et al., 2006), respectively. Although the Als2 gene in a targeted allele can be transcribed by its own promoter, the normal protein translation is terminated after first 14 amino acids, resulting the peptide lacks all the functional domains of ALS2. Third line was generated by using promoter trap gene targeting to replace exons 3 and 4 with SA-IRES-βgeo-pA cassette encoding bifunctional LacZ-neomycin fusion protein (Devon et al., 2006), and expected to produce fusion protein carrying only seven amino acid residues originated from ALS2 at the N-terminus. Forth line was produced by replacing exon 2 and part of exon 3 with the NEO cassette, resulting in a complete lack of transcription for the Als2-coded sequence (Julien and Kriz, 2006). Final line reported contain the Als2-null allele generated by replacing the 3′-half of exon 4 and intron 4 with the NEO cassette, which results in a truncated ALS2 peptide (174 aa) containing a portion of the N-terminal RLD (Yamanaka et al., 2006). Although there are slight differences in the gene targeting strategy, the translation of the full-length functional ALS2 protein is completely disrupted in all these mice (i.e., Als2 KO mice) (Cai et al., 2005; Hadano et al., 2006; Devon et al., 2006; Yamanaka et al., 2006; Julien and Kriz, 2006).

Surprisingly, these studies combined demonstrate that absence of ALS2 does not develop ALS2-related disease phenotypes in mice; they show no obvious developmental and reproductive abnormalities with normal life-span. However, Als2 KO mice exhibit age-dependent deficits in motor

S. Hadano et al./Neurochemistry International 51 (2007) 74–84

**Immature neuron**  
**Mature neuron**

- **Dendrite**
- **Endosome**
- **Lysosome**
- **Mitochondria**
- **Actin-fibers**
- **Neurofilaments**
- **Lamellipodia**
- **Filopodia**
- **Growth cone**

- **Golgi**
- **ER**
- **Nucleus**
- **Axon**
- **Synapse**

**ALS2 functions**
- Endosome fusion/trafficking (Rab5GEF)
- Actin organization (Rac1GEF?)
- Axon/neurite outgrowth (Rac1/Rab5GEF?)
- Axonal transport ?
- Endocytosis and vesicle trafficking ?
- Anti-cytotoxic effects

Fig. 3. Schematic representation of the proposed functions of ALS2 in developing and matured neurons. ALS2 plays a role in membrane/vesicular trafficking and axonal outgrowth in neurons. Further, a neuroprotective role for ALS2 against cytotoxicity; i.e., mutant SOD1-mediated toxicity, oxidative stress, and excitotoxicity, has recently been documented (see text).

coordination and motor learning, and aged Als2 KO mice or primary cultured motor neurons derived from these mice are slightly vulnerable to oxidative stress (Cai et al., 2005). Additional findings include a significant decrease in the size of cortical neurons (Devon et al., 2006) and a progressive axonal degeneration in the lateral spinal cord (Yamanaka et al., 2006) or in corticospinal tract (Julien and Kriz, 2006). Further, Als2 KO neurons shows a disturbance in endosomal transport of a subset of trophic receptors, such as insulin-like growth factor 1 (IGF1) and brain-derived neurotrophic factor (BDNF) (Devon et al., 2006). We have shown that Als2 KO mice develop an age-dependent, slowly progressive loss of cerebellar Purkinje cells, disturbance of spinal motor neurons associated with astrocytosis and microglial activation, and evidences for the deficits in endosome dynamics (Hadano et al., 2006). Most recently, it has been reported that Als2 KO mice exhibit lymphopenia and abnormal hematopoietic function, suggesting an involvement of immune system in the pathogenesis (Erie et al., 2007). Collectively, while loss of ALS2 does not produce severe phenotypes in mice, there are recognizable subclinical and cellular dysfunctions. Thus, it is anticipated that these animals should provide a useful means with which to investigate the ALS2 functions in vivo and the molecular pathogenesis underlying the ALS2-linked MNDs.

### 4.4. ALS2-interacting and its related proteins

The protein-protein interactions are one of the key molecular basis not only to the organizations of the structural protein complexes, such as cytoskeletal elements, but also to the regulation and coordination of an immense amount of molecular signals within and/or between cells. Evidence is accumulating that ALS2 is a GEF for the Rab5 small GTPase family, and also acts as a regulator for the Rho-type GTPase

Rac1. In fact, ALS2 specifically interacts with Rab5 and Rac1 (see above). Thus, ALS2 might involve in the regulation of Rab5- and Rac1-mediated signaling pathways, via their direct interactions, in the cells. To understand the pathogenesis of the ALS2-linked MNDs, the clarification of the ALS2-mediated molecular signaling both in normal and pathological conditions is essential. Here, we introduce recent advances in the identification and characterization of the ALS2-interacting proteins, which will provide a novel insight into the studies on the ALS2 functions and the pathogenesis.

#### 4.4.1. SOD1: Cu/Zn-superoxide dismutase

Mutations in the SOD1 gene account for the autosomal dominant ALS with adult onset (ALS1) (Rosen et al., 1993). The SOD1 gene encodes Cu/Zn-superoxide dismutase (SOD1), and SOD1 mutants cause motor neuron degeneration through gain of toxic properties (Rakhit and Chakrabarty, 2006). Recently, it has been demonstrated that overexpression of ALS2 specifically inhibits SOD1 mutant-induced neurotoxicity in NSC34 cells (Kanekura et al., 2004). This protective effect is dependent on the DH/PH domain of ALS2, and most importantly, ALS2 directly binds to SOD1 mutant, but not to the wild-type SOD1 via its DH/PH domain (Kanekura et al., 2004). Further, such ALS2-mediated neuroprotective function against mutant SOD1-induced motor neuron death exerts through the activation of the Rac1/phosphatidylinositol 3-kinase (PI3K)/Akt3 prosurvival pathway, which is also dependent on the DH/PH domain of ALS2 (Kanekura et al., 2005; Matsuoka and Nishimoto, 2005). Thus, at least in a certain cell type, ALS2 antagonizes SOD1 mutant-induced neurotoxicity via their direct interaction and the activation of a particular anti-apoptotic signaling pathway. However, there are mutually contradictory aspects to their findings. Deficiency in ALS2 does not affect the pathogenesis of SOD1<sup>G93A</sup> mice on an
S. Hadano et al./Neurochemistry International 51 (2007) 74–84

Als2-null background (Lin et al., 2007). Besides that, a missense mutation in ALS2 is also cytotoxic, and cell death induced by neurotoxic stimuli, such as N-methyl-D-aspartate (NMDA) and staurosporine, is significantly suppressed by expressing wild-type ALS2, which are both independent of the interaction with SOD1 (Panzeri et al., 2006). Rather the protection by ALS2 occurs through a signaling event impinging on a common cell-death pathway, in which mutant ALS2 decreases, while wild-type ALS2 increases the Bcl-xL:Bax ratio (Panzeri et al., 2006), albeit a direct molecular association yet to be demonstrated.

### 4.4.2. GRIP1: glutamate receptor interacting protein 1
Glutamate-mediated excitotoxicity, which is primarily mediated by α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA)-type glutamate receptors, involved in degeneration of spinal motor neurons in the sporadic ALS (Kawahara et al., 2004). AMPA receptor is a tetramer composing of a various combination of the AMPA-type glutamate receptor subunit 1–4 (GluR1–GluR4). GluR2 is of particular interest, because GluR2-containing AMPA receptors are calcium-impermeable and neurons lacking this type of receptors become more vulnerable to excitotoxicity (Kwak and Weiss, 2006). Glutamate receptor interacting protein 1 (GRIP1) is one of the regulators for GluR2 trafficking and the dynamics of GluR2-containing AMPA receptors (Hirai, 2001). Recently, GRIP1 has been identified as an ALS2-interacting protein, and shown to be associated through the N-terminal RLD of ALS2 (Lai et al., 2006). Importantly, loss of ALS2 results in a decrease of GluR2, and thus calcium-impermeable GluR2-containing AMPA receptors, at the synaptic/cell surface of Als2 KO neurons, rendering neurons more susceptibility to glutamate receptor-mediated neurotoxicity (Lai et al., 2006). This suggests that ALS2 could modulate, through the interaction with GRIP1, AMPA receptor trafficking and contributes to a neuroprotective role against excitotoxicity.

### 4.4.3. ALS2CL: ALS2 C-terminal like
Recently, we and others have identified a novel ALS2 homolog, ALS2 C-terminal like (ALS2CL) highly homologous to the C-terminal half of ALS2, which is expressed in various tissues (Hadano et al., 2004; Devon et al., 2005). ALS2CL lacks the RLD, but contains the ALS2-like Rab5GEF domain; the MORN/VPS9 domain. ALS2CL exhibits a specific but a relatively weak Rab5-GEF activity with accompanying rather strong Rab5-binding properties (Hadano et al., 2004). Further, ALS2CL shows a different intracellular localization and has different effects on the Rab5-meidated endosomal morphology compared with those of ALS2. As aforementioned, ALS2 forms homo-oligomeric complex through its C-terminal regions (Kunita et al., 2004). Although a majority of ALS2CL is present as a rather dimeric form, it could interact with the ALS2-oligomer, resulting in the formation of the large ALS2/ALS2CL heteromeric complex *in vitro* (Suzuki-Utsunomiya et al., 2007). Importantly, in cultured cells, ALS2CL dominantly suppresses endosome enlargement induced by a constitutively active form of ALS2; ALS2_695-1657aa, ALS2

lacking the RLD, and results in an extensive perinuclear tubulomembranous phenotype co-localizing with microtubules, which are also dependent upon the ALS2CL-ALS2 interaction (Suzuki-Utsunomiya et al., 2007). Thus, ALS2CL is a novel ALS2-interacting protein that may contribute toward understandings of ALS2-mediated endosome dynamics in cells.

### 5. Conclusions
Since the discovery of the ALS2 gene as a causative for a number of juvenile recessive MNDs in 2001 (Hadano et al., 2001a; Yang et al., 2001), extensive efforts toward the delineation of the ALS2 functions in normal as well as pathological conditions are being studied as described in this review. Although there are still many questions unanswered, it has become increasingly clear that ALS2 contributes to the small GTPase-mediated molecular as well as cellular events, and implicating in endosome dynamics, cytoskeletal organizations, anti-cytotoxicity, and neuronal development/maintenance (Figs. 2 and 3). Most recently, we have found that ALS2 is also involved in an unfamiliar endocytic mechanism, called macropinocytosis, and the following macropinosome trafficking and fusion (Kunita et al., 2007). Loss of the ALS2 functions due to the ALS2 mutations ought to perturb such molecular and cellular mechanisms, thereby resulting in cellular dysfunction and ultimately in cell death. There are also increasing evidence accumulating that intracellular vesicle/membrane trafficking and endosome dynamics play crucial roles in the pathogenesis not only in MNDs other than ALS2/PLSJ/IAHSP (Evans et al., 2006; Kanekura et al., 2006; Mannan et al., 2006; Shirane and Nakayama, 2006; Goytain et al., 2007), but also in other conditions of neurodegenerative diseases, such as Alzheimer’s disease (Grbovic et al., 2003), frontotemporal dementia (Skibinski et al., 2005), Parkinson’s disease (Cooper et al., 2006), and Huntington’s disease (Pal et al., 2006). Thus, membrane dynamics and its dysfunction may underlie the pathogenesis of a variety of neurodegenerative diseases, leading to a unifying comprehension of neuronal dysfunction. Nevertheless, it should also be emphasized that further studies, which could fill the gaps between understandings of molecular/cellular function and clinical manifestations, thereby uncovering the mechanisms of a selective neurodegeneration seen in all the neurodegenerative diseases, will be required to develop proper and effective remedies for these devastating diseases.

### Acknowledgements
This work was funded by Japan Science and Technology Agency (JST) (to J-EI), the Ministry of Health, Labour and Welfare (to J-EI), a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (to SH), Japan Brain Foundation (to SH), and The Ichiro Kanehara Foundation (to SH). RK and KS-U are supported by a 2006 Tokai University School of Medicine Research Aid, and AO is supported by a Research Fellowship for Young Scientist from JSPS.
References

Al-Chalabi, A., Hansen, V.K., Simpson, C.L., Xi, J., Hosler, B.A., Powell, J.F., McKenna-Yasek, D., Shaw, C.E., Leigh, P.N., Brown Jr., R.H., 2003. Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis. Neurogenetics 4, 221–222.

Ben-Hamida, M., Hentati, F., Ben-Hamida, C., 1990. Hereditary motor system diseases (chronic juvenile amyotrophic lateral sclerosis). Brain 113, 347–363.

Boillée, S., Vande Velde, C., Cleveland, D.W., 2006. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39–59.

Cai, H., Lin, X., Xie, C., Laird, F.M., Lai, C., Wen, H., Chiang, H.C., Shim, H., Farah, M.H., Hoke, A., Price, D.L., Wong, P.C., 2005. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knockout mice but predisposes neurons to oxidative stress. J. Neurosci. 25, 7567–7574.

Carney, D.S., Davies, B.A., Horazdovsky, B.F., 2006. Vps9 domain-containing proteins: activators of Rab5 GTPases from yeast to neurons. Trends Cell Biol. 16, 27–35.

Chevalier-Larsen, E., Holzbaur, E.L.F., 2006. Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta 1762, 1094–1108.

Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, R.D., Labaer, J., Rochet, J.C., Bonini, N.M., Lindquist, S., 2006. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 313, 324–328.

Côté, J.-F., Vuori, K., 2002. Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. J. Cell Sci. 115, 4901–4913.

Da Silva, J.S., Dotti, C.G., 2002. Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis. Nat. Rev. Neurosci. 3, 694–704.

Dasso, M., 2001. Running on Ran: nuclear transport and the mitotic spindle. Cell 104, 321–324.

Delprato, A., Merithew, E., Lambright, D.G., 2004. Structure, exchange determinants, and family-wide rab specificity of the tandem helical bundle and Vps9 domains of Rabex-5. Cell 118, 607–617.

Devon, R.S., Orban, P.C., Gerrow, K., Barbieri, M.A., Schwab, C., Cao, L.P., Helm, J.R., Bissada, N., Cruz-Aguado, R., Davidson, T.L., Witmer, J., Metzler, M., Lam, C.K., Tetzlaff, W., Simpson, E.M., McCaffery, J.M., El-Husseini, A.E., Leavitt, B.R., Hayden, M.R., 2006. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 103, 9595–9600.

Devon, R.S., Schwab, C., Topp, J.D., Orban, P.C., Yang, Y.Z., Pape, T.D., Helm, J.R., Davidson, T.L., Rogers, D.A., Gros-Louis, F., Rouleau, G., Horazdovsky, B.F., Leavitt, B.R., Hayden, M.R., 2005. Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiol. Dis. 18, 243–257.

Devon, R.S., Helm, J.R., Rouleau, G.A., Leitner, Y., Lerman-Sagie, T., Lev, D., Hayden, M.R., 2003. The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clin. Genet. 64, 210–215.

Erie, E.A., Shim, H., Smith, A.L., Lin, X., Keyvanfar, K., Xie, C., Chen, J., Cai, H., 2007. Mice deficient in the ALS2 gene exhibit lymphopenia and abnormal hematopoietic function. J. Neuroimmunol. 182, 226–231.

Etienne-Manneville, S., Hall, A., 2002. Rho GTPases in cell biology. Nature 420, 629–635.

Evans, K., Keller, C., Pavur, K., Glasgow, K., Conn, B., Lauring, B., 2006. Interaction of two hereditary spastic paraplegia gene products, spastin and atlastin, suggests a common pathway for axonal maintenance. Proc. Natl. Acad. Sci. U.S.A. 103, 10666–10671.

Eymard-Pierre, E., Yamanaka, K., Haeussler, M., Kress, W., Gauthier-Barichard, F., Combes, P., Cleveland, D.W., Boespflug-Tanguy, O., 2006. Novel missense mutation in ALS2 gene results in infantile ascending hereditary spastic paralysis. Ann. Neurol. 59, 976–980.

Eymard-Pierre, E., Lesca, G., Dollet, S., Santorelli, F.M., di Capua, M., Bertini, E., Boespflug-Tanguy, O., 2002. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am. J. Hum. Genet. 71, 518–527.

Fink, J.K., 2001. Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin. Neurol. 21, 199–207.

Goytain, A., Hines, R.M., El-Husseini, A., Quamme, G.A., 2007. NIPA1(SPG6), the basis for autosomal dominant form of hereditary spastic paraplegia, encodes a functional Mg²⁺ transporter. J. Biol. Chem. 282, 8060–8068.

Grbovic, O.M., Mathews, P.M., Jiang, Y., Schmidt, S.D., Dinakar, R., Summers-Terio, N.B., Ceresa, B.P., Nixon, R.A., Cataldo, A.M., 2003. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular β-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Aβ production. J. Biol. Chem. 278, 31261–31268.

Gros-Louis, F., Gaspar, C., Rouleau, G.A., 2006. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 956–972.

Gros-Louis, F., Meijer, I.A., Hand, C.K., Dube, M.P., MacGregor, D.L., Seni, M.H., Devon, R.S., Hayden, M.R., Andermann, F., Andermann, E., Rouleau, G.A., 2003. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann. Neurol. 53, 144–145.

Hadano, S., Benn, S.C., Kakuta, S., Otomo, A., Sudo, K., Kunita, R., Suzuki-Utsunomiya, K., Mizumura, H., Shefner, J.M., Cox, G.A., Iwakura, Y., Brown Jr., R.H., Ikeda, J.-E., 2006. Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Hum. Mol. Genet. 15, 233–250.

Hadano, S., Ikeda, J.-E., 2005. Purification and functional analyses of ALS2 and its homologue. Methods Enzymol. 403, 310–321.

Hadano, S., Otomo, A., Suzuki-Utsunomiya, K., Kunita, R., Yanagisawa, Y., Showguchi-Miyata, J., Mizumura, H., Ikeda, J.-E., 2004. ALS2CL, the novel protein highly homologous to the carboxy-terminal half of ALS2, binds to Rab5 and modulates endosome dynamics. FEBS Lett. 575, 64–70.

Hadano, S., Hand, C.K., Osuga, H., Yanagisawa, Y., Otomo, A., Devon, R.S., Miyamoto, N., Showguchi-Miyata, J., Okada, Y., Singaraja, R., Figlewicz, D.A., Kwiatkowski, T., Hosler, B.A., Sagie, T., Skaug, J., Nasir, J., Brown Jr., R.H., Scherer, S.W., Rouleau, G.A., Hayden, M.R., Ikeda, J.-E., 2001a. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 29, 166–173.

Hadano, S., Yanagisawa, Y., Skaug, J., Fischer, K., Nasir, J., Martindale, D., Koop, B.F., Scherer, S.W., Nicholson, D.W., Rouleau, G.A., Ikeda, J.-E., Hayden, M.R., 2001b. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33–q34: candidate genes for ALS2. Genomics 71, 200–213.

Hadano, S., Nichol, K., Brinkman, R.R., Nasir, J., Martindale, D., Koop, B.F., Nicholson, D.W., Scherer, S.W., Ikeda, J.-E., Hayden, M.R., 1999. A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33–q34. Genomics 55, 106–112.

Hand, C.K., Devon, R.S., Gros-Louis, F., Rochefort, D., Khoris, J., Meininge, V., Bouchard, J.P., Camu, W., Hayden, M.R., Rouleau, G.A., 2003. Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. Arch. Neurol. 60, 1768–1771.

Hentati, A., Bejaoui, K., Pericak-Vance, M.A., Hentati, F., Speer, M.C., Hung, W.Y., Figlewicz, D.A., Haines, J., Rimmler, J., Ben Hamida, C.B., Hamida, M.B., Brown Jr., R.H., Siddique, T., 1994. Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33–q35. Nat. Genet. 7, 425–428.

Hirai, H., 2001. Modification of AMPA receptor clustering regulates cerebellar synaptic plasticity. Neurosci. Res. 39, 261–267.

Hosler, B.A., Sapp, P.C., Berger, R., O’Neill, G., Bejaoui, K., Hamida, M.B., Hentati, F., Chin, W., McKenna-Yasek, D., Haines, J.L., Patterson, D., Horvitz, H.R., Brown Jr., R.H., Day, C.B., 1998. Refined mapping and characterization of the recessive familial amyotrophic lateral sclerosis locus (ALS2) on chromosome 2q33. Neurogenetics 2, 34–42.

Jacquier, A., Buhler, E., Schafer, M.K., Bohl, D., Blanchard, S., Beclin, C., Haase, G., 2006. Alsin/Rac1 signaling controls survival and growth of spinal motoneurons. Ann. Neurol. 60, 105–117.

James, P.A., Talbot, K., 2006. The molecular genetics of non-ALS motor neuron diseases. Biochim. Biophys. Acta 1762, 986–1000.

Julien, J.P., Kriz, J., 2006. Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1013–1024.

Kanekura, K., Nishimoto, I., Aiso, S., Matsuoka, M., 2006. Characterization of amyotrophic lateral sclerosis-linked P56S mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J. Biol. Chem. 281, 30223–30233.

Kanekura, K., Hashimoto, Y., Kita, Y., Sasabe, J., Aiso, S., Nishimoto, I., Matsuoka, M., 2005. A Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway, triggered by Alsinf, the product of the ALS2 gene, antagonizes Cu/Zn-superoxide dismutase (SOD1) mutant-induced motor neuronal cell death. J. Biol. Chem. 280, 4532–4543.

Kanekura, K., Hashimoto, Y., Niikura, T., Aiso, S., Matsuoka, M., Nishimoto, I., 2004. Alsinf, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J. Biol. Chem. 279, 19247–19256.

Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I., Kwak, S., 2004. Glutamate receptors: RNA editing and death of motor neurons. Nature 427, 801.

Kress, J.A., Kuhnlein, P., Winter, P., Ludolph, A.C., Kassubek, J., Muller, U., Sperfeld, A.D., 2005. Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Ann. Neurol. 58, 800–803.

Kunita, R., Otomo, A., Mizumura, H., Suzuki-Utsunomiya, K., Hadano, S., Ikeda, J.-E., 2007. The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis. J. Biol. Chem. 282, 16599–16611.

Kunita, R., Otomo, A., Mizumura, H., Suzuki, K., Showguchi-Miyata, J., Yanagisawa, Y., Hadano, S., Ikeda, J.-E., 2004. Homo-oligomerization of ALS2 through its unique carboxyl-terminal regions is essential for the ALS2-associated Rab5 guanine nucleotide exchange activity and its regulatory function on endosome trafficking. J. Biol. Chem. 279, 38626–38635.

Kwak, S., Weiss, J.H., 2006. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr. Opin. Neurobiol. 16, 281–287.

Lai, C., Xie, C., McCormack, S.G., Chiang, H.C., Michalak, M.K., Lin, X., Chandran, J., Shim, H., Shimoji, M., Cookson, M.R., Huganir, R.L., Rothstein, J.D., Price, D.L., Wong, P.C., Martin, L.J., Zhu, J.J., Cai, H., 2006. Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J. Neurosci. 26, 11798–11806.

Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A.F., Boguski, M.S., Brockway, K.S., Byrnes, E.J., Chen, L., Chen, L., Chen, T.M., Chin, M.C., Chong, J., Crook, B.E., Czaplinska, A., Dang, C.N., Datta, S., Dee, N.R., Desaki, A.L., Desta, T., Diep, E., Dolbeare, T.A., Donelan, M.J., Dong, H.W., Dougherty, J.G., Duncan, B.J., Ebbert, A.J., Eichele, G., Estin, L.K., Faber, C., Facer, B.A., Fields, R., Fischer, S.R., Fliss, T.P., Frensley, C., Gates, S.N., Glattfelder, K.J., Halverson, K.R., Hart, M.R., Hohmann, J.G., Howell, M.P., Jeung, D.P., Johnson, R.A., Karr, P.T., Kawal, R., Kidney, J.M., Knapik, R.H., Kuan, C.L., Lake, J.H., Laramee, A.R., Larsen, K.D., Lau, C., Lemon, T.A., Liang, A.J., Liu, Y., Luong, L.T., Michaels, J., Morgan, J.J., Morgan, R.J., Mortrud, M.T., Mosqueda, N.F., Ng, L.L., Ng, R., Orta, G.J., Overly, C.C., Pak, T.H., Parry, S.E., Pathak, S.D., Pearson, O.C., Puchalski, R.B., Riley, Z.L., Rockett, H.R., Rowland, S.A., Royall, J.J., Ruiz, M.J., Sarno, N.R., Schaffnit, K., Shapovalova, N.V., Sivisay, T., Slaughterbeck, C.R., Smith, S.C., Smith, K.A., Smith, B.I., Sodt, A.J., Stewart, N.N., Stumpf, K.R., Sunkin, S.M., Sutram, M., Tam, A., Teemer, C.D., Thaller, C., Thompson, C.L., Varnam, L.R., Visel, A., Whitlock, R.M., Wohnoutka, P.E., Wolkey, C.K., Wong, V.Y., Wood, M., Yaylaoglu, M.B., Young, R.C., Youngstrom, B.L., Yuan, X.F., Zhang, B., Zwingman, T.A., Jones, A.R., 2007. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445, 168–176.

Lesca, G., Eymard-Pierre, E., Santorelli, F.M., Cusmai, R., Di Capua, M., Valente, E.M., Attia-Sobol, J., Plauchu, H., Leuzzi, V., Ponzone, A., Boespflug-Tanguy, O., Bertini, E., 2003. Infantile ascending hereditary spastic paralysis (IAHSP): clinical features in 11 families. Neurology 60, 674–682.

Lin, X., Shim, H., Cai, H., 2007. Deficiency in the ALS2 gene does not affect the motor neuron degeneration in SOD1G93A transgenic mice. Neurobiol. Aging [Epub ahead of print].

Lodhi, I.J., Chiang, S.H., Chang, L., Vollenweider, D., Watson, R.T., Inoue, M., Pessin, J.E., Saltiel, A.R., 2007. Gapex-5, a Rab31 guanine nucleotide exchange factor that regulates Glut4 trafficking in adipocytes. Cell Metab. 5, 59–72.

Luo, L., 2000. Rho GTPases in neuronal morphogenesis. Nat. Rev. Neurosci. 1, 173–180.

Mannan, A.U., Krawen, P., Sauter, S.M., Boehm, J., Chronowska, A., Paulus, W., Neesen, J., Engel, W., 2006. ZFYVE27 (SPG33), a novel spastin-binding protein, is mutated in hereditary spastic paraplegia. Am. J. Hum. Genet. 79, 351–357.

Matsuoka, M., Nishimoto, I., 2005. Anti-ALS activity of alsin, the product of the ALS2 gene, and activity-dependent neurotrophic factor. Neurodegener. Dis. 2, 135–138.

Miaczynska, M., Christoforidis, S., Giner, A., Shevchenko, A., Utenweiler-Joseph, S., Habermann, B., Wilm, M., Parton, R.G., Zerial, M., 2004. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116, 445–456.

Millecamps, S., Gentil, B.J., Gros-Louis, F., Rouleau, G., Julien, J.P., 2005. Alsinf is partially associated with centrosome in human cells. Biochim. Biophys. Acta 1745, 84–100.

Nagano, I., Murakami, T., Shiote, M., Manabe, Y., Hadano, S., Yanagisawa, Y., Ikeda, J.-E., Abe, K., 2003. Single-nucleotide polymorphisms in uncoding regions of ALS2 gene of Japanese patients with autosomal-recessive amyotrophic lateral sclerosis. Neurol. Res. 25, 505–509.

Otomo, A., Hadano, S., Okada, T., Mizumura, H., Kunita, R., Nishijima, H., Showguchi-Miyata, J., Yanagisawa, Y., Kohiki, E., Suga, E., Yasuda, M., Osuga, H., Nishimoto, T., Narumiya, S., Ikeda, J.-E., 2003. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum. Mol. Genet. 12, 1671–1687.

Pal, A., Severin, F., Lommer, B., Shevchenko, A., Zerial, M., 2006. Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington’s disease. J. Cell Biol. 172, 605–618.

Panzeri, C., De Palma, C., Martinuzzi, A., Daga, A., De Polo, G., Bresolin, N., Miller, C.C., Tudor, E.L., Clementi, E., Bassi, M.T., 2006. The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain 129, 1710–1719.

Pasinelli, P., Brown, R.H., 2006. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci. 7, 710–723.

Rakhit, R., Chakrabarty, A., 2006. Structure, folding, and misfolding of Cu, Zn superoxide dismutase in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 1762, 1025–1037.

Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O’Regan, J.P., Deng, H.X., Rahmani, Z., Krizus, A., McKenna-Yasek, D., Cayabyab, A., Gaston, S.M., Berger, R., Tanzi, R.E., Halperin, J.J., Herzfeldt, B., Van den Bergh, R., Hung, W.Y., Bird, T., Deng, G., Mulder, D.W., Smyth, C., Laing, N.G., Soriano, E., Pericak-Vance, M.A., Haines, J., Rouleau, G.A., Gusella, J.S., Horvitz, H.R., Brown Jr., R.H., 1993. Mutation in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62.

Rossman, K.L., Der, C.J., Sondek, J., 2005. GEF means go: turning on Rho GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167–180.

Shaw, P.J., 2005. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry 76, 1046–1057.

Shirane, M., Nakayama, K.I., 2006. Protrudin induces neurite formation by directional membrane trafficking. Science 314, 818–821.

Simpson, C.L., Al-Chalabi, A., 2006. Amyotrophic lateral sclerosis as a complex genetic disease. Biochim. Biophys. Acta 1762, 973–985.

Skibinski, G., Parkinson, N.J., Brown, J.M., Chakrabarti, L., Lloyd, S.L., Hummerich, H., Nielsen, J.E., Hodges, J.R., Spillantini, M.G., Thusgaard, T., Brandner, S., Brun, A., Rossor, M.N., Gade, A., Johannsen, P., Sorensen, S.A., Gydesen, S., Fisher, E.M., Collinge, J., 2005. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806–808.

Snider, W.D., Zhou, F.-Q., Zhong, Z., Markus, A., 2002. Signaling the pathway to regeneration. Neuron 35, 13–16.

Stenmark, H., Olkkonen, V.M., 2001. The Rab GTPase family. Genome Biol. 2, 3007.1–3007.7.

Suzuki-Utsunomiya, K., Hadano, S., Otomo, A., Kunita, R., Mizumura, H., Osuga, H., Ikeda, J.-E., 2007. ALS2CL, a novel ALS2-interactor, modulates ALS2-mediated endosome dynamics. Biochem. Biophys. Res. Commun. 354, 491–497.

Takeshima, H., Komazaki, S., Nishi, M., Iino, M., Kangawa, K., 2000. Junctophilins: a novel family of junctional membrane complex proteins. Mol. Cell 6, 11–22.

Topp, J.D., Gray, N.W., Gerard, R.D., Horazdovsky, B.F., 2004. Alsip is a Rab5 and Rac1 guanine nucleotide exchange factor. J. Biol. Chem. 279, 24612–24623.

Tudor, E.L., Perkinton, M.S., Schmidt, A., Ackerley, S., Brownlee, J., Jacobson, N.J., Byers, H.L., Ward, M., Hall, A., Leigh, P.N., Shaw, C.E., McLoughlin, D.M., Miller, C.C., 2005. ALS2/Alsip regulates Rac-PAK signaling and neurite outgrowth. J. Biol. Chem. 280, 34735–34740.

Van Aelst, L., Symons, M., 2002. Role of Rho family GTPases in epithelial morphogenesis. Genes Dev. 16, 1032–1054.

Verma, A., Bradley, W.G., 2001. Atypical motor neuron disease and related motor syndromes. Semin. Neurol. 21, 177–187.

Vetter, I.R., Wittinghofer, A., 2001. The guanine-nucleotide-binding switch in three dimensions. Science 294, 1299–1304.

Yamanaka, K., Miller, T.M., McAlonis-Downes, M., Chun, S.J., Cleveland, D.W., 2006. Progressive spinal axonal degeneration and slowness in ALS2-deficient mice. Ann. Neurol. 60, 95–104.

Yamanaka, K., Vande Velde, C., Eymard-Pierre, E., Bertini, E., Boespflug-Tanguy, O., Cleveland, D.W., 2003. Unstable mutants in the peripheral endosomal membrane component ALS2 cause early-onset motor neuron disease. Proc. Natl. Acad. Sci. U.S.A. 100, 16041–16046.

Yang, Y., Hentati, A., Deng, H.X., Dabbagh, O., Sasaki, T., Hirano, M., Hung, W.Y., Ouahchi, K., Yan, J., Azim, A.C., Cole, N., Gascon, G., Yagmour, A., Ben-Hamida, M., Pericak-Vance, M., Hentati, F., Siddique, T., 2001. The gene encoding alsip, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29, 160–165.

Zhang, X., He, X., Fu, X.Y., Chang, Z., 2006. Varp is a Rab21 guanine nucleotide exchange factor and regulates endosome dynamics. J. Cell Sci. 119, 1053–1062.

Zerial, M., McBride, H., 2001. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 107–117.
